Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.

BACKGROUND: The conventional frontline therapy for fit patients with chronic lymphocytic leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab (Mabthera(®), Roche Products Ltd) targets the CD20 antigen, which is expressed at low levels in CLL. The standard dose of rituximab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Health Technol Assess
Autors principals: Howard, Dena R, Munir, Talha, McParland, Lucy, Rawstron, Andy C, Chalmers, Anna, Gregory, Walter M, O'Dwyer, John L, Smith, Alison, Longo, Roberta, Varghese, Abraham, Smith, Alexandra, Hillmen, Peter
Format: Artigo
Idioma:Inglês
Publicat: NIHR Journals Library 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494513/
https://ncbi.nlm.nih.gov/pubmed/28628003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21280
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars